Top Markets
#1 TENDIES TENDIES +59.72%
#2 Threshold Network Threshold Network +48.06%
#3 Cash Cat Cash Cat +25.61%
#4 Akedo Akedo +23.45%
#5 OSK OSK +16.28%
#6 Kinetiq Kinetiq +15.49%
#7 Maple Finance Maple Finance +14.59%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Falcon Finance Falcon Finance +12.36%
#10 Magma Finance Magma Finance +12.35%
Coin of the day
TENDIES TENDIES
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Classifica tra le azioni #17294
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Prezzo delle azioni
$1.33
Ultima sincronizzazione: 2026-09-01
Capitalizzazione di mercato
$246.43M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-23.56%
Paese
US
Scambia Neumora Therapeutics, Inc. Common Stock (NMRA)

Categoria

Healthcare
Ricavi di Neumora Therapeutics, Inc. Common Stock (NMRA)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Neumora Therapeutics, Inc. Common Stock, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Neumora Therapeutics, Inc. Common Stock da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH